临时60天经皮外周神经电刺激治疗慢性疼痛的纵向结局:回顾性分析
该回顾性队列研究纳入125例接受临时60天经皮外周神经电刺激的慢性疼痛患者,主要结局为术后NRS疼痛评分较操作日降低≥30%。102例有完整数据者中24%达到主要应答标准,敏感性分析应答率为8%-14%,低于适应证特异性试验报告的水平。电极移位、脱出或断裂集中于无应答者,54%患者合并至少一种精神健康诊断。
要点
- 临时60天经皮PNS主要应答率24%,敏感性分析仅8%-14%,低于既往适应证试验。
- 19%患者提前移除装置,无应答者提前移除比例(22%)高于应答者(13%)。
- 电极移位、脱出或断裂集中于无应答者,可能是可干预的疗效不佳因素。
核心结论
- 临时60天经皮PNS在24%患者中达到主要结局定义的≥30%疼痛缓解,各敏感性分析应答率为8%-14%,均低于适应证特异性试验报告。
- 电极移位、脱出或断裂集中于无应答者,可能为可干预的次优结局因素。
- 该人群精神健康共病患病率高,需前瞻性评估其作为治疗应答预测因素的价值。
研究设计与样本
- 回顾性队列研究,纳入2021年4月至2025年9月在Massachusetts General Hospital和Brigham and Women's Hospital接受临时60天经皮PNS的125例慢性疼痛患者。
- 主要结局为治疗应答,定义为操作日至术后NRS疼痛评分中位数降低≥30%;敏感性分析采用≥50%阈值及术后最大NRS锚点。
- 次要结局包括阿片类药物用量变化(MME)和不良事件发生率;纵向疼痛轨迹采用线性混合效应模型分析。
主要发现
- 125例中102例有完整操作日及随访疼痛评分数据,其中24例(24%)达到主要应答阈值(≥30%降低,基于术后NRS中位数)。
- 敏感性分析应答率:≥50%阈值联合术后NRS中位数为14例(14%),≥30%阈值联合术后最大NRS为13例(13%),≥50%阈值联合术后最大NRS为8例(8%)。
- 全部患者中24例(19%)提前移除PNS装置:11例(9%)因无效或疼痛加重或新发感觉异常,13例(10%)因电极移位或脱出、电极断裂、为行MRI而移除、感染及皮肤刺激等其他原因。
- 非应答者提前移除率(22%)高于应答者(13%);35例(28%)基线有阿片类药物使用的患者中,7例在1年时有可记录的MME变化,5例增加、2例减少。
- 54%患者合并至少一种精神健康诊断。
关键数值与推荐
- 主要应答标准:操作日至术后NRS疼痛评分中位数降低≥30%,对应慢性疼痛既定共识的临床意义改善。
- 敏感性分析阈值:≥50%降低;术后疼痛锚点:术后NRS中位数或术后最大NRS;组合后应答率8%-14%。
临床怎么用
- 对慢性疼痛患者行临时60天经皮PNS前,应告知主要应答率约24%、敏感性分析应答率8%-14%,低于适应证特异性试验报告水平。
- 关注电极移位、脱出或断裂风险,尤其无应答者提前移除率更高,需加强装置监测与随访。
- 该人群精神健康共病比例高(54%),临床评估时应将精神健康共病纳入综合考量,但其对治疗应答的预测价值尚待前瞻性研究。
局限性
- 回顾性队列设计,125例中仅102例有完整操作日及随访疼痛评分数据。
- 应答率基于不同术后疼痛锚点和阈值的敏感性分析,结果范围较宽(8%-14%)。
- 基线阿片类药物使用患者中仅7例有1年时可记录的MME变化,阿片类药物用量变化数据有限。
- 精神健康共病作为治疗应答预测因素的价值需前瞻性评估,本研究未提供其与应答关系的分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous peripheral nerve stimulation (PNS) has emerged as a minimally invasive neuromodulation therapy for treating chronic pain, and additional real-world data continue to inform its effectiveness and safety in routine practice. METHODS: We conducted a retrospective cohort study of 125 patients who underwent temporary 60-day percutaneous PNS at Massachusetts General Hospital and Brigham and Women's Hospital between April 2021 and September 2025. The primary outcome was treatment response, defined as ≥30% reduction from day-of-procedure to median postprocedural Numerical Rating Scale (NRS) pain score, corresponding to clinically meaningful improvement per established consensus for chronic pain. Sensitivity analyses examined responder rates under alternative thresholds (≥50%) and postprocedure pain anchors (maximum NRS), including the combination of these. Secondary outcomes included change in opioid utilization (morphine milligram equivalents (MME)) and incidence of adverse events. Longitudinal pain trajectories were examined using linear mixed-effects models. RESULTS: Of 125 patients, 102 had complete procedure-day and follow-up pain score data. Among these, 24 (24%) met the primary responder threshold of ≥30% reduction from day-of-procedure to median postprocedural NRS score. Sensitivity analyses yielded responder rates of 14 (14%) at the ≥50% threshold using median postprocedural NRS, 13 (13%) at the ≥30% threshold using maximum postprocedural NRS, and eight (8%) at the ≥50% threshold using maximum postprocedural NRS. For all patients, early PNS device removal occurred in 24 patients (19%): 11 (9%) due to lack of efficacy or worsening pain or new paresthesia and 13 (10%) for other reasons, including lead migration or dislodgement, lead fracture, removal to facilitate MRI, infection, and skin irritation; early removal was more frequent among non-responders than responders (22% vs 13%). Most patients were opioid-naïve at baseline; among the 35 patients (28%) with baseline opioid use, seven patients had a documentable change in MME at 1 year, five with an increase, and two with a decrease. For all patients, more than half (54%) carried at least one comorbid mental health diagnosis. CONCLUSIONS: Patients with percutaneous 60-day PNS showed ≥30% pain reduction in 24% of patients using the primary outcome (median postprocedural NRS), with responder rates spanning 8%-14% across sensitivity analyses depending on the postprocedural pain anchor and threshold applied. Response rates fell short of those reported in indication-specific trials across all outcome definitions. Lead migration, dislodgement, or fracture were concentrated among non-responders and may represent a modifiable contributor to suboptimal outcomes. The high prevalence of mental health comorbidity in this population warrants prospective evaluation as a predictor of treatment response.
引用
- Chiang MC, Smith MR, Karri J, et al. Longitudinal outcomes following temporary 60-day percutaneous peripheral nerve stimulation for chronic pain: a retrospective analysis. Reg Anesth Pain Med. 2026. PMID: 42498450. doi:10.1136/rapm-2026-108123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。